

09/936362

**Sim & McBurney**  
Patent and Trade-mark Agents

Please Quote  
Our ref. 1038-1190 MIS/ac

Your ref.

Writer's Ext. 239

E-mail: [mistewart@sim-mcburney.com](mailto:mistewart@sim-mcburney.com)

November 30, 2001

**VIA COURIER**


The Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231  
United States of America

Dear Sirs:

**RE: U.S. Patent Application No. 09/936,362**  
**Filing Date: March 16, 2000**  
**Applicant: Sheena Loosmore et al**  
**RECOMBINANT HAEMOPHILUS INFLUENZA**  
**ADHESIN PROTEINS**

Please find enclosed an Information Disclosure Statement and copies of the references listed therein with respect to each of the references cited in the specification, in the International Search Report received on the corresponding International application and in prior U.S. application No. 09/936,362.

Respectfully submitted,

  
Michael I. Stewart  
Registration No. 24,973

M.I. Stewart/ac  
Encl.


JPO5 Rev U PCT/PTG 03 DEC 2001

310 University Avenue  
6th floor  
Toronto, Canada  
M5C 1R7


Telephone (416) 595-1155  
Fax (416) 595-1163

IDS/#6  
PCT 2/8/02

MICHAEL I STEWART  
ROGER T. HUGHES, Q.C.  
TONI POLSON ASHTON  
JOHN H. WOODLEY  
KENNETH D. MCKAY  
TIMOTHY M. LOWMAN  
STEPHEN M. LANE  
ARTHUR B. RENAUD  
STEPHEN J. PERRY  
PATRICIA A. RAE  
DAVID A. RUSTON  
L.E. TRENT HORNE  
LOLA A. BARTOSZEWICZ  
THOMAS T. RIEDER  
WARREN J. GALLOWAY  
URSULA M. MCGUINNESS  
ROBERT C.T. LIANG  
ELIZABETH VALENTINA  
LESLEY M. MORRISON  
GEOFFREY B.C. DE KLEINE  
SENIOR CONSULTANTS  
PETER W. MCBURNEY  
BRENDA L. BOARDMAN  
TECHNICAL ASSISTANTS  
KIMBERLY A. MC MANUS, PH.D.  
WENDY M. NOSS, B.A., C.L.B.



**RECEIVED**  
**FEB 06 2002**  
**TECH CENTER 1600/2900**

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-1190 MIS:ac	SERIAL NO. 09/936,362
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		APPLICANT: Sheena Loosmore et al.	
		FILING DATE March 16, 2000	GROUP ---

## U.S. PATENT DOCUMENTS

*INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
		4,496,538	Jan/85	Gordon	424	92	
		5,808,024	Sep. 15, 1998	Sasaki et al.	536	23.1	
		4,855,283	Aug. 8, 1989	Lockhoff	424	27.8	
		4,952,496	Aug. 28, 1990	Studier	435	91	
		4,258,029	Mar. 24, 1981	Moloney	424	88	
		5,646,259	July 8, 1997	St. Geme III	536	23.1	
		5,194,254	Mar. 16, 1993	Barber	424	85.8	
		5,843,463	Dec. 1, 1998	Krivan	424	256.1	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION	
		WO 95/34308	Dec. 21, 1995	PCT			YES	NO
		WO 96/30519	Oct. 3, 1996	PCT				
		WO 96/02648	Feb. 1, 1996	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1 ✓	Berkowitz et al. 1987. J. Pediatr. 110:509.
	2	Claesson et al. 1989. J. Pediatr. 114:97.
	3 ✓	Black, S.B., H.R. Shinefield, B. Fireman, R. Hiatt, M. Polen, E. Vittinghoff, The Northern California Kaiser Permanent Vaccine Study Center Pediatrics Group. Efficacy in infancy of oligosaccharide conjugate <i>Haemophilus influenzae</i> type b (HbOC) vaccine in a United States population of 61,080 children. 1991. Pediatr. Infect. Dis. J. 10:97-104.
	4 ✓	Madore, D.V. 1996. Impact of immunization on <i>Haemophilus influenzae</i> type b disease. Infectious Agents and Disease 5:8-20.
	5 ✓	Bluestone, C.D. 1982. Current concepts in otolaryngology. Otitis media in children: to treat or not to treat? N. Engl. J. Med. 306:1399-1404.
EXAMINER:		DATE CONSIDERED:


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

RECEIVED

TECH CENTER 1600/2808

FEB 06 2002

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 1038-1190 MIS:ac	SERIAL NO. 09/936,362	RECEIVED FEB 06 2002 TECH CENTER 1600/2900
	APPLICANT: Sheena Loosmore et al.		
	FILING DATE Mach 16, 2000	GROUP ---	



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
6 ✓	St. Geme, J.W. and D. Cutter. (1995) Evidence that surface fibrils expressed by <i>Haemophilus influenzae</i> type B promote attachment to human epithelial cells. <i>Molec. Microbiol.</i> 15:77-85.
7 ✓	Barenkamp, S.J., and E. Leininger. 1992. Cloning, expression, and DNA sequence analysis of genes encoding nontypeable <i>Haemophilus influenzae</i> high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of <i>Bordetella pertussis</i> . <i>Infect. Immun.</i> 60:1302-1313.
8 ✓	Barenkamp, S.J. and J.W. St. Geme. (1996) Identification of a second family of high-molecular-weight adhesion proteins expressed by non-typable <i>Haemophilus influenzae</i> . <i>Molec. Microbiol.</i> 19:1215-1223.
9 ✓	St. Geme, J.W. D. Cutter, and S.J. Barenkamp. (1996) Characterization of the genetic locus encoding <i>Haemophilus influenzae</i> type b surface fibrils. <i>J. Bact.</i> 178:6281-6287.
10 ✓	St. Geme III, J.W., S. Falkow, and S.J. Barenkamp. 1993. High-molecular-weight proteins of nontypeable <i>Haemophilus influenzae</i> mediate attachment to human epithelial cells. <i>Proc. Natl. Acad. Sci. USA</i> 90:2875-2879.
11 ✓	Barenkamp, S.J. 1996. Immunization with high-molecular-weight adhesion proteins of nontypeable <i>Haemophilus influenzae</i> modifies experimental otitis media in chinchillas. <i>Infect. Immun.</i> 64:1246-1251.
12 ✓	Tabor, S., and C.C. Richardson. 1985. A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes. <i>Proc. Natl. Acad. Sci. USA</i> 82:1074-1078.
13 ✓	Patient, M.E., and D.K. Summers. 1993. ColE1 multimer formation triggers inhibition of <i>Escherichia coli</i> cell division. <i>Molec. Microbiol.</i> 9:1089-1095.
14 ✓	Yang, Y.-P., S.M. Loosmore, B. Underdown, and M.H. Klein. 1998. Nasopharyngeal colonization with nontypeable <i>H. influenzae</i> in chinchillas. <i>Infect. Immun.</i> 66:1973-1980.
15 ✓	O'Hagan, DT. 1992. Oral delivery of vaccines. Formulation and clinical pharmacokinetic considerations. <i>Clin. Pharmacokinet</i> 22(t): 1-10.
16	Ulmer et al. 1993. <i>Curr. Opin. Invest. Drugs</i> 2:983-989.
17 ✓	Lockhoff, O., 1991. Glycolipids as immunomodulators: Synthesis and properties.
18 ✓	Nixon-George A., et al., 1990. The adjuvant effect of stearyl tyrosine on a recombinant subunit hepatitis B surface antigen. <i>J. Immunol</i> 144 (12):4798-4802.
19 ✓	Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. <i>Nature</i> 227:680-685.
EXAMINER: _____ DATE CONSIDERED: _____	

